Cargando…

A Patient With Miller Fisher Syndrome With Positive GQ1b and Aquaporin-4 Antibodies: Will There Be an Aquaporin-4 Antibody Associated Disorder?

There have been many advancements in the field of neuromyelitis optica and neuromyelitis optica spectrum disorder since the discovery of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein antibodies. It is also recognized that the pathological features associated with myelin oligodendrocyte...

Descripción completa

Detalles Bibliográficos
Autores principales: Aylia, Fatin, Johri, Karn, Spencer, Riley, Chu, David, Deriss, Mehron, Peng, Davin, Eskenazi, Jonathan, Liu, Antonio K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423626/
https://www.ncbi.nlm.nih.gov/pubmed/37581199
http://dx.doi.org/10.7759/cureus.43428
_version_ 1785089492744404992
author Aylia, Fatin
Johri, Karn
Spencer, Riley
Chu, David
Deriss, Mehron
Peng, Davin
Eskenazi, Jonathan
Liu, Antonio K
author_facet Aylia, Fatin
Johri, Karn
Spencer, Riley
Chu, David
Deriss, Mehron
Peng, Davin
Eskenazi, Jonathan
Liu, Antonio K
author_sort Aylia, Fatin
collection PubMed
description There have been many advancements in the field of neuromyelitis optica and neuromyelitis optica spectrum disorder since the discovery of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein antibodies. It is also recognized that the pathological features associated with myelin oligodendrocyte glycoprotein antibodies are beyond the domain of neuromyelitis optica spectrum disorder and there is a separate nomenclature, namely myelin oligodendrocyte glycoprotein antibody associated disease. Currently, there is no aquaporin-4 antibody associated disorder, even though aquaporin-4 antibodies are not as widely present in other disorders.  Miller Fisher syndrome (MFS) is a variant of Guillain Barré syndrome, in which there are positive GQ1b antibodies with no evidence of myelitis or optic neuritis. MFS is not considered a component of neuromyelitis optica spectrum disorder. We report on a patient with MFS that was positive for GQ1b and aquaporin-4 antibodies but negative for myelin oligodendrocyte glycoprotein antibodies and is devoid of any features of neuromyelitis optica spectrum disorder. This finding may lead to investigations and reports of other pathologies that are associated with the aquaporin-4 antibody. 
format Online
Article
Text
id pubmed-10423626
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-104236262023-08-14 A Patient With Miller Fisher Syndrome With Positive GQ1b and Aquaporin-4 Antibodies: Will There Be an Aquaporin-4 Antibody Associated Disorder? Aylia, Fatin Johri, Karn Spencer, Riley Chu, David Deriss, Mehron Peng, Davin Eskenazi, Jonathan Liu, Antonio K Cureus Neurology There have been many advancements in the field of neuromyelitis optica and neuromyelitis optica spectrum disorder since the discovery of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein antibodies. It is also recognized that the pathological features associated with myelin oligodendrocyte glycoprotein antibodies are beyond the domain of neuromyelitis optica spectrum disorder and there is a separate nomenclature, namely myelin oligodendrocyte glycoprotein antibody associated disease. Currently, there is no aquaporin-4 antibody associated disorder, even though aquaporin-4 antibodies are not as widely present in other disorders.  Miller Fisher syndrome (MFS) is a variant of Guillain Barré syndrome, in which there are positive GQ1b antibodies with no evidence of myelitis or optic neuritis. MFS is not considered a component of neuromyelitis optica spectrum disorder. We report on a patient with MFS that was positive for GQ1b and aquaporin-4 antibodies but negative for myelin oligodendrocyte glycoprotein antibodies and is devoid of any features of neuromyelitis optica spectrum disorder. This finding may lead to investigations and reports of other pathologies that are associated with the aquaporin-4 antibody.  Cureus 2023-08-13 /pmc/articles/PMC10423626/ /pubmed/37581199 http://dx.doi.org/10.7759/cureus.43428 Text en Copyright © 2023, Aylia et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Neurology
Aylia, Fatin
Johri, Karn
Spencer, Riley
Chu, David
Deriss, Mehron
Peng, Davin
Eskenazi, Jonathan
Liu, Antonio K
A Patient With Miller Fisher Syndrome With Positive GQ1b and Aquaporin-4 Antibodies: Will There Be an Aquaporin-4 Antibody Associated Disorder?
title A Patient With Miller Fisher Syndrome With Positive GQ1b and Aquaporin-4 Antibodies: Will There Be an Aquaporin-4 Antibody Associated Disorder?
title_full A Patient With Miller Fisher Syndrome With Positive GQ1b and Aquaporin-4 Antibodies: Will There Be an Aquaporin-4 Antibody Associated Disorder?
title_fullStr A Patient With Miller Fisher Syndrome With Positive GQ1b and Aquaporin-4 Antibodies: Will There Be an Aquaporin-4 Antibody Associated Disorder?
title_full_unstemmed A Patient With Miller Fisher Syndrome With Positive GQ1b and Aquaporin-4 Antibodies: Will There Be an Aquaporin-4 Antibody Associated Disorder?
title_short A Patient With Miller Fisher Syndrome With Positive GQ1b and Aquaporin-4 Antibodies: Will There Be an Aquaporin-4 Antibody Associated Disorder?
title_sort patient with miller fisher syndrome with positive gq1b and aquaporin-4 antibodies: will there be an aquaporin-4 antibody associated disorder?
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423626/
https://www.ncbi.nlm.nih.gov/pubmed/37581199
http://dx.doi.org/10.7759/cureus.43428
work_keys_str_mv AT ayliafatin apatientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder
AT johrikarn apatientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder
AT spencerriley apatientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder
AT chudavid apatientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder
AT derissmehron apatientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder
AT pengdavin apatientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder
AT eskenazijonathan apatientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder
AT liuantoniok apatientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder
AT ayliafatin patientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder
AT johrikarn patientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder
AT spencerriley patientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder
AT chudavid patientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder
AT derissmehron patientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder
AT pengdavin patientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder
AT eskenazijonathan patientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder
AT liuantoniok patientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder